These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24797458)

  • 1. A novel method to produce Influenza A virus matrix protein M1 Capsid Like Particles (CLPs).
    Baniasadi V; Lal SK
    J Virol Methods; 2014 Sep; 205():1-2. PubMed ID: 24797458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
    Yang JR; Chen CY; Kuo CY; Cheng CY; Lee MS; Cheng MC; Yang YC; Wu CY; Wu HS; Liu MT; Hsiao PW
    Antiviral Res; 2016 Feb; 126():8-17. PubMed ID: 26593980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
    Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
    Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs.
    Pyo HM; Masic A; Woldeab N; Embury-Hyatt C; Lin L; Shin YK; Song JY; Babiuk S; Zhou Y
    Vaccine; 2012 Feb; 30(7):1297-304. PubMed ID: 22207090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks.
    Prel A; Le Gall-Reculé G; Cherbonnel M; Grasland B; Amelot M; Jestin V
    Avian Dis; 2007 Mar; 51(1 Suppl):484-9. PubMed ID: 17494615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens.
    Song BM; Kang HM; Lee EK; Jung SC; Kim MC; Lee YN; Kang SM; Lee YJ
    Vaccine; 2016 Jan; 34(5):678-686. PubMed ID: 26691568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
    Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
    Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses.
    Kapczynski DR; Tumpey TM; Hidajat R; Zsak A; Chrzastek K; Tretyakova I; Pushko P
    Vaccine; 2016 Mar; 34(13):1575-1581. PubMed ID: 26868083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological characteristics and immunological properties in Muscovy ducks of H5N6 virus-like particles composed of HA-TM/HA-TM
    Qin J; Zhang Y; Shen X; Gong L; Xue C; Cao Y
    Avian Pathol; 2019 Feb; 48(1):35-44. PubMed ID: 30404538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
    Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
    Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievement of avian influenza virus-like particles that could be used as a subunit vaccine against low-pathogenic avian influenza strains in ducks.
    Prel A; Le Gall-Reculé G; Jestin V
    Avian Pathol; 2008 Oct; 37(5):513-20. PubMed ID: 18798027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease.
    Shen H; Xue C; Lv L; Wang W; Liu Q; Liu K; Chen X; Zheng J; Li X; Cao Y
    Virus Res; 2013 Dec; 178(2):430-6. PubMed ID: 24050994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus.
    Ren Z; Ji X; Meng L; Wei Y; Wang T; Feng N; Zheng X; Wang H; Li N; Gao X; Jin H; Zhao Y; Yang S; Qin C; Gao Y; Xia X
    Virus Res; 2015 Mar; 200():9-18. PubMed ID: 25599603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice.
    Tao P; Luo M; Zhu D; Qu S; Yang Z; Gao M; Guo D; Pan Z
    Viral Immunol; 2009 Jul; 22(4):273-81. PubMed ID: 19594398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Construction and immunogenicity of recombinant bacteriophage T7 vaccine expressing M2e peptides of avian influenza virus].
    Xu H; Wang YW; Tang YH; Zheng QS; Hou JB
    Bing Du Xue Bao; 2013 Jun; 29(4):376-81. PubMed ID: 23895000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).
    Matassov D; Cupo A; Galarza JM
    Viral Immunol; 2007 Sep; 20(3):441-52. PubMed ID: 17931114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a fully human monoclonal antibody against extracellular domain of matrix protein 2 of influenza A virus.
    Ozawa T; Jin A; Tajiri K; Takemoto M; Okuda T; Shiraki K; Kishi H; Muraguchi A
    Antiviral Res; 2011 Sep; 91(3):283-7. PubMed ID: 21726583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.